Summary of COPT Defense Properties Conference Call Company Overview - COPT Defense Properties is a specialized real estate investment trust (REIT) focused on mission-critical assets supporting national defense activities in the U.S. [8][9] - The company operates 207 properties, primarily located near U.S. defense installations in Maryland, Virginia, Alabama, and Texas, with 80% of the portfolio dedicated to high-security operations [8][9]. Key Financial Metrics - Current occupancy rate is 94.5%, with 95.5% leased overall and 96.5% leased in defense assets [10][11]. - Historical low occupancy was approximately 87% before repositioning to a pure defense focus [10][13]. - The company has maintained occupancy above 93% since its strategic shift [13]. Lease Structure and Tenant Retention - COPT's leases with the U.S. government are structured with annual escalators and typically include 1-year leases with multiple automatic renewals [14][15]. - The retention rate with government tenants is nearly 100%, with no full building non-renewals in 34 years [16][19]. - The company has a strong track record with defense contractors, averaging 80% retention over the last decade [92]. Development and Growth Opportunities - COPT has a development capacity of around 8 million square feet, primarily in priority defense locations [52]. - The company can self-fund $250 million to $300 million annually in new development without external capital [55]. - Significant growth opportunities are anticipated in Huntsville, Alabama, particularly related to the Redstone Arsenal and the Golden Dome initiative, which has a funding allocation of $175 billion over several years [41][45][50]. Market Dynamics and Strategic Positioning - The company emphasizes its unique position in the defense sector, with a focus on providing facilities for knowledge-based defense installations rather than engaging directly in defense contracting [78][81]. - COPT's business model is resilient to government shutdowns, as rent payments are mandated by government regulations [72]. - The company views current geopolitical tensions as potential entry points for stock investment rather than direct catalysts for business growth [74][78]. Financial Health and Credit Rating - COPT's target debt to EBITDA ratio is approximately 6x, with a current ratio of 5.9x [101]. - The company was recently upgraded by Moody's to Baa2 from Baa3, reflecting its strong cash flow and occupancy rates [104][110]. Future Outlook - The company is exploring opportunities to replicate its success in Huntsville in other markets, with potential for expansion in the next 5 to 10 years [141][142]. - COPT is actively engaging with new entrants in the defense space, providing support and facilities for startups in cybersecurity and other technology sectors [133][140]. Conclusion - COPT Defense Properties is well-positioned in the defense real estate market, with strong occupancy rates, a solid lease structure, and significant growth opportunities driven by government demand and strategic initiatives. The company's focus on mission-critical assets and its ability to self-fund development projects enhance its resilience and potential for future growth.

Financial Data and Key Metrics Changes - NextNav finished Q4 2025 with approximately $152 million in cash equivalents and short-term investments, indicating a strong liquidity position [12] - The company reported a net loss of roughly $68 million for the quarter, primarily due to non-cash losses of approximately $48 million associated with the change in the fair value of derivative and warrants liability [13] Business Line Data and Key Metrics Changes - NextNav has begun operating the world's first 5G-powered PNT network, marking a significant step towards commercialization [10] - The partnership with Japan's MetCom highlights the international scalability of NextNav's platform and the demand for resilient terrestrial 5G-based 3D PNT solutions [11] Market Data and Key Metrics Changes - The FCC has sent a draft notice of proposed rulemaking (NPRM) focused on PNT technologies to the White House OMB, which is a critical step in the regulatory process [4] - The discussions at industry events emphasized the importance of PNT capabilities as a transformative application for 5G and 6G networks [9] Company Strategy and Development Direction - NextNav aims to provide a terrestrial complement and backup to GPS, addressing vulnerabilities in current systems and enhancing national security [6][10] - The company is focused on advancing its technology and commercialization efforts while maintaining a strong governance structure [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the path toward an FCC vote on the NPRM, with a clear line of sight to a Report and Order [25] - The company is committed to strengthening U.S. economic and national security through its innovative solutions [25] Other Important Information - NextNav's solution is designed to be future-proof and does not require taxpayer funding, which positions the company favorably in the market [6] - The company has a significant number of warrants expiring in 2026 that could deliver over $200 million in additional capital depending on stock price performance [12] Q&A Session Summary Question: Has the company seen the contents of the NPRM sent to the OMB? - Management confirmed that they have not seen the contents as it is part of the inter-agency review process [15] Question: Will the NPRM likely include a 10 by 5 channel for more precise PNT? - Management indicated that they are testing towards a 10+5 capability as part of their commercialization efforts and are confident in meeting the requirements [16] Question: What learnings have been gained from the MetCom relationship? - Management highlighted the international opportunity presented by the MetCom partnership and its potential to accelerate commercialization in the U.S. [20]

Columbus McKinnon Conference Call Summary Company Overview - **Company**: Columbus McKinnon (NasdaqGS:CMCO) - **Industry**: Industrial Equipment and Automation - **Market Presence**: Operates in over 70 countries with a total addressable market of $35 billion - **Employee Count**: Over 7,000 employees - **Business Focus**: Leading global lifting and automation solutions for material handling requirements Key Points and Arguments Investment Thesis - Columbus McKinnon aims to deliver outsized revenue growth through a diverse portfolio including precision conveyance, automation, and linear motion products, alongside a core lifting business expected to grow at GDP plus rates [2][4] - The company anticipates $70 million in net cost synergies from operational efficiencies and improved fixed cost absorption [3][12] - Cash generation is strong, with historical cash conversion exceeding net income, expected to improve through synergy attainment [3][4] Debt Management - The company plans to accelerate debt repayment, targeting a debt-to-EBITDA ratio below 4 times by fiscal 2028, with a long-term goal of 2 times [4][10] Market Dynamics - Demand remains strong despite geopolitical tensions, with a robust pipeline of opportunities in both short and long cycle projects [18][19] - Columbus McKinnon has approximately $50 million in annual sales to the Middle East, with some potential impacts from geopolitical disruptions [19] Pricing and Tariffs - A 7% price increase implemented in July fully covered tariff costs, with expectations for tariffs to become less of a headwind moving forward [28][30] - The company is exploring potential tariff refunds, which could positively impact financials [29][30] Acquisition of Kito Crosby - The acquisition is expected to enhance Columbus McKinnon's competitive position in the lifting solutions market, with significant opportunities for revenue and cost synergies [10][50] - The integration management office is fully staffed, focusing on synergy realization and value creation [42][61] - Early wins in commercial and revenue synergies have been noted, with ongoing efforts to streamline costs and improve operational efficiencies [45][46] Customer Engagement and Cross-Selling - There are significant cross-selling opportunities between the legacy Columbus McKinnon and Kito Crosby customer bases, with efforts to enhance customer experience through digitization and improved service delivery [56][58][78] - The company aims to position itself as a one-stop shop for lifting solutions, leveraging its expanded product portfolio [73][78] Financial Projections - Free cash flow is projected to be around $170 million, factoring in the impact of the Kito Crosby acquisition and divestitures [94][95] - The company expects to achieve margin expansion and revenue growth through strategic initiatives and operational improvements [14][70] Competitive Positioning - Columbus McKinnon maintains a strong margin profile compared to peers, with a focus on safety, reliability, and total cost of ownership as key differentiators [88][90] - The company is positioned to outperform traditional lifting peers, with a focus on delivering value through comprehensive solutions [102][106] Additional Important Insights - The company has a well-defined commercial strategy to ensure effective integration and realization of synergies from the acquisition [61][62] - Ongoing investments in digital capabilities are aimed at enhancing customer interactions and operational efficiencies [58][60] - The leadership team is confident in the company's ability to navigate current market challenges and capitalize on growth opportunities [43][70]

Financial Data and Key Metrics Changes - In 2025, the company reported a loss from operations of $139.3 million, primarily due to payroll, general business expenses, and professional fees related to capital market and asset deployment activities [33] - The loss before income taxes was $110.2 million, which included interest and dividend income of $29.1 million from marketable securities [33] - Cash used in operating activities was $82.2 million, with an adjusted figure of $69.2 million, aligning with the guidance of $65 million-$80 million for 2025 [34] - The company ended 2025 with cash and marketable securities totaling $1.4 billion and raised an additional $1.182 billion in early 2026, completing a $1.5 billion ATM program [36] Business Line Data and Key Metrics Changes - The company transitioned from product development to active project deployment across all business units in 2025, including the groundbreaking of the first Aurora powerhouse at Idaho National Laboratory [3][4] - Significant progress was made in the fuel business unit, with the completion of fast-spectrum plutonium criticality experiments and advancements in fuel recycling initiatives [4][9] - The isotopes business unit is expanding with the construction of the Groves radioisotope test reactor and the Idaho Radiochemistry Laboratory, which is expected to generate revenue in the near term [26][27] Market Data and Key Metrics Changes - The U.S. nuclear policy has shifted towards a more execution-oriented posture, providing a strong tailwind for the nuclear sector, which benefits the company's strategic positioning [4][5] - The demand for clean, reliable baseload power is increasing across various sectors, including data centers and industrial customers, which aligns with the company's power business strategy [6][7] Company Strategy and Development Direction - The company aims to build a vertically integrated nuclear platform encompassing power, fuel, and isotopes, which is designed to unlock multiple complementary value streams over time [5][12] - The strategy includes leveraging federal support mechanisms such as tax credits and loan guarantees to enhance project funding pathways [4][5] - The company is focused on building a more integrated nuclear development model to unlock nuclear energy abundance, with ongoing projects across all three business units [16] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of the DOE's Nuclear Lifecycle Innovation Campuses in modernizing the nuclear fuel cycle and improving investment efficiency [15] - The company is optimistic about the regulatory environment, expecting the NRC to issue a new framework for converting DOE-authorized facilities to NRC-licensed facilities, which could expedite future projects [52][56] - Management emphasized the need for flexibility in capital allocation and cash management to support growth opportunities in 2026 and beyond [35] Other Important Information - The company is actively pursuing partnerships for fuel supply and recycling, including a joint venture with Centrus focused on uranium deconversion [25] - The Idaho Radiochemistry Laboratory has obtained its NRC materials license, marking a significant operational milestone [26] Q&A Session Summary Question: Status on commercialization and customer pipeline - Management noted that Meta is a key anchor customer, and discussions are ongoing with other potential customers, including military and industrial sectors [38][39] Question: Breakdown of CapEx guidance for 2026 - Management refrained from providing a detailed breakdown but indicated that significant spending will occur across all business units, particularly in Idaho and Ohio [41][43] Question: Update on COLA timing and NRC licensing - Management clarified that DOE authorization allows for faster project execution and that they are preparing for NRC licensing while leveraging experiences from the DOE pathway [49][50][52]

Summary of Neurocrine Biosciences Conference Call Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Date of Conference**: March 17, 2026 - **Key Speakers**: Kyle Gano (CEO), Todd Tushla (Head of IR) Key Points 1. Financial Performance - **2025 Revenue**: Approximately $2.8 billion, representing a **22% year-over-year growth** [4] - **Ingrezza Revenue**: $2.51 billion in 2025, with a **9% year-over-year growth** and double-digit volume growth [5] - **2026 Revenue Guidance**: Expected to be between **$2.7 billion and $2.8 billion** [11] - **Price Trends**: Anticipated **4%-5% price decline** year-over-year for Ingrezza due to expanded access [12] 2. Product Performance - **Ingrezza**: - Eighth year of commercialization with strong sales performance. - Focus on expanding prescriber base, targeting **30% new prescribers** [6] - Anticipated strong year with **double-digit volume growth** [31] - **CRENESSITY**: - First year of commercial sales generated **$300 million** in revenue, capturing **10% of the CH market** [7] - High reimbursement rates with **80% of dispensed scripts reimbursed** [7] - Focus on educational support for physicians and patients to change the standard of care [8] 3. Pipeline and Future Developments - **Phase 3 Trials**: - Osavampator and direclidine expected to deliver data in **2027** [8] - NBI-570 (M1M4 dual agonist) in schizophrenia and NBI-890 (next-generation VMAT2 inhibitor) in phase 2 trials [9][10] - **Next-Generation VMAT2 Program**: - Focus on long-acting injectable formulations to improve patient compliance [72] - **CRF1 Antagonist (NBIP-1435)**: - In phase 1, moving to phase 2/3 later this year, offering a long-acting injectable option [80] 4. Market Dynamics and Competitive Landscape - **Market Access**: - 70% of TD and HD patients under existing contracts, providing a strong market position [36] - **Competitor Analysis**: - Teva's MFP implementation in 2027 and 2028 may impact pricing strategies [36] - **Regulatory Environment**: - Ongoing negotiations with Medicare plans for 2027, with expectations for adjacent MFP products [37] 5. Strategic Focus - **Execution and Data Delivery**: - Emphasis on executing current strategies and delivering data across phase 2 and phase 3 programs in 2027 [10] - **Sustainable Innovation**: - Commitment to a diversified pipeline and innovation engine to support long-term growth [86] 6. Additional Insights - **Patient Compliance**: - Importance of addressing patient reauthorization processes and maintaining access to prescriptions [44] - **Market Sensitivity**: - Anticipation of emotional responses to new patient start forms, with a focus on consistent growth trends [42] Conclusion Neurocrine Biosciences is positioned for continued growth with a strong financial profile, a diversified product portfolio, and a robust pipeline of upcoming clinical data. The company is focused on execution and market access strategies to navigate competitive pressures and regulatory challenges while aiming to enhance patient care through innovative therapies.

Summary of RadNet Presentation at KeyBank's Healthcare Forum Company Overview - **Company**: RadNet - **Industry**: Outpatient diagnostic imaging services - **Operations**: Over 400 centers across the U.S., primarily in 10 states - **Key Features**: Complementary digital health platform, self-developed IT platform, and AI integration [1][2] 2025 Performance and 2026 Outlook - **2025 Challenges**: Faced California wildfires and severe winter weather impacting operations [5] - **2025 Growth**: Achieved unprecedented growth in MRI volume (over 11%), CT volume (mid-single digits), and PET CT (over 14%) [6] - **Acquisitions**: Completed tuck-in acquisitions, including 13 centers in Southwest Florida and 6 centers in Indiana [7] - **Digital Health Growth**: Nearly 100% growth in digital health revenue, ending the year with $92 million [7] - **2026 Guidance**: Projected revenue growth of 17%-19% for imaging centers and close to 50% for digital health [8] Business Model and Market Position - **Symbiotic Relationship**: Digital health division is an extension of the imaging center business, aimed at improving workflow and efficiency [10][11] - **Technological Advancements**: Emphasis on AI, machine learning, and new technology to transform the industry [12] Revenue and EBITDA Growth Drivers - **Revenue Growth Factors**: - Acquisitions contributing to inorganic growth - Continued same-center performance with advanced imaging driving growth [14][15] - Pricing benefits from Medicare and commercial payer mix [15] - **EBITDA Growth**: Expected to grow faster than revenue, driven by operational efficiencies and expansion of hospital joint ventures [13] Advanced Imaging Trends - **Market Shift**: Over 200 basis point shift towards advanced imaging due to technology advancements and aging population [19] - **Capacity Improvements**: Upgraded MRI scanners and AI-powered scheduling to increase patient throughput [20][21] Hospital Joint Ventures - **JV Model Benefits**: - Hospitals seek partnerships to adapt to outpatient care trends and improve operational efficiency [23][24] - RadNet benefits from hospital relationships to capture imaging referrals [27] - **Current Status**: 36% of centers in joint ventures, with potential for growth beyond 50% [28] Digital Health Division - **Growth Projections**: Guiding for 45%-55% growth in annual recurring revenue (ARR) with a target of $140 million [35] - **Key Products**: - EBCD program with 46% patient adoption - iCAD acquisition expected to enhance digital health revenue [36][37] - Growth in AI clinical solutions for lung and thyroid health [38] Gleamer Acquisition - **Strategic Fit**: Gleamer enhances RadNet's AI capabilities, with significant ARR growth and cross-selling opportunities [40][43] - **Market Position**: Combined entity positioned as the largest radiology AI company globally [44] Capital Allocation Strategy - **Opportunistic Approach**: Focus on imaging center acquisitions and joint ventures, with a disciplined approach to capital deployment [46][47] - **Financial Position**: Anticipating over $100 million in free cash flow, maintaining liquidity for future opportunities [48] Regulatory Considerations - **Site Neutrality Impact**: Potential positive implications for RadNet, as hospitals may seek partnerships to adapt to regulatory changes [50][52] This summary encapsulates the key points discussed during the RadNet presentation, highlighting the company's performance, strategic direction, and market dynamics.

Financial Data and Key Metrics Changes - Total revenue for the third quarter was $24.6 million, representing a 63% increase compared to the prior year period [9][20] - Gross margin improved to 52.6%, up 9 percentage points year-over-year and 200 basis points sequentially, marking the ninth consecutive quarter of sequential gross margin expansion [9][20] - GAAP net loss was $34.2 million, compared to a GAAP net loss of $21.8 million in the prior year period [24] Business Line Data and Key Metrics Changes - The company accepted over 5,400 prescriptions for the ASSURE System, reflecting a 58% year-over-year increase in prescriptions [9][20] - The conversion rate improved to approximately 46%, up from an adjusted conversion rate of 43% in the prior year period [21] Market Data and Key Metrics Changes - The wearable cardioverter defibrillator (WCD) market is estimated to have grown in the low to mid-teens percentage on a dollar basis in calendar year 2025 [10][11] - The company believes the WCD market will expand into a multi-billion-dollar market in the coming years [10] Company Strategy and Development Direction - The company aims to achieve gross margins of 70% or more over the next few years, supported by strong revenue growth and margin expansion [10][20] - A strategic collaboration with Biobeat Technologies was announced to enhance diagnostic insights for patients, integrating their technology into the product portfolio [13][14] - The company is expanding its sales organization to penetrate existing accounts and attract new prescribers, targeting geographies with high volumes of WCD prescriptions [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong performance and the foundation built for durable growth [18][19] - The management highlighted the importance of clinical data from the ACE-PAS study in driving clinician engagement and market expansion [12][48] Other Important Information - The company became an approved Florida managed Medicaid provider, which is expected to enhance market share in Florida [16][60] - The monthly Medicare reimbursement rate for WCDs increased by 2% to $3,589 as of January 1 [17] Q&A Session Summary Question: Thoughts on early 2027 model and $133 million consensus - Management is confident in delivering top-tier med tech growth in 2027 and will provide more details at the next earnings call [29] Question: Acceleration in WCD market growth - Management noted that increased commercial team size and clinical results are driving market growth, with expectations for continued acceleration [31][34] Question: Prescription growth sources - Approximately 70%-75% of prescription growth is attributed to market share shift, with 25% from new prescribers [38] Question: Competitive environment and pricing - Management indicated no pricing headwinds and emphasized ongoing competition without significant obstacles from competitors [42] Question: Florida Medicaid provider status impact - The approval is expected to enhance growth in Florida, although it will take time to see full benefits [60] Question: CapEx spending as a leading indicator - Management indicated that CapEx spending is aligned with the growth strategy, with expectations for continued investment in inventory and service levels [83] Question: Cash burn outlook - Management expects cash burn to remain in the mid-$20 million range for the next year, excluding specific investments [85]

Financial Data and Key Metrics Changes - ClearPoint Neuro reported total revenues of $37 million for the year ended December 31, 2025, an increase from $31.4 million in 2024, with $1.2 million attributed to the acquisition of IRRAS Holdings, Inc. [10] - Gross margin for 2025 was 61%, consistent with 2024 [12] - Net cash flows used in operating activities increased to $23.9 million in 2025, up from $8.9 million in 2024 [19] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 10% to $19 million in 2025, up from $17.3 million in 2024, driven by increased product sales [11] - Neurosurgery Navigation revenue grew to $14.8 million in 2025, including $1.2 million from IRRAflow, primarily due to an expanded installed base and the market release of new products [11] - Capital equipment and software revenue was $3.1 million for 2025, showing a slight decrease compared to previous periods [12] Market Data and Key Metrics Changes - The company expects revenues for 2026 to be in the range of $52 million to $56 million, reflecting factors such as FDA communications regarding rare diseases and integration efforts from the IRRAS acquisition [8] - The company is targeting a $1 billion market opportunity across four product segments, expecting double-digit growth in each segment for 2026 [6][21] Company Strategy and Development Direction - ClearPoint Neuro is focused on developing a complete neuro ecosystem for minimally invasive treatments, including cell and gene therapies [4] - The company has entered two phases of growth strategy: "Fast Forward" to penetrate existing markets and "Essential Everywhere" to build a new market for commercial cell and gene therapy delivery [6][7] - The company aims to achieve 20% market share in its existing $1 billion market and generate $200 million in annual revenue [34] Management's Comments on Operating Environment and Future Outlook - Management highlighted the strong financial performance in Q4 2025 and expressed optimism about the future, emphasizing the importance of their biopharma partnerships and clinical trials [21][26] - The management acknowledged challenges related to FDA communications on rare diseases but remains focused on larger patient populations and established markets [40][42] Other Important Information - The company has invested over $100 million in the past five years to build a strong foundation, including a robust pipeline of development programs and an expanded manufacturing footprint [5] - ClearPoint Neuro has over 60 active biopharma partners and is involved in more than 25 active clinical trials [5][24] Q&A Session Summary Question: Clarification on 2026 guidance and organic growth - Management discussed the impact of FDA communications on rare diseases and integration priorities from the IRRAS acquisition on revenue guidance [39][40] - The company expects balanced growth between organic and inorganic sources, with all segments projected to grow in double digits [45][46] Question: Pathway to $200 million revenue - Management indicated a growth rate of 15%-20% could be expected as the company integrates IRRAS and expands its market share [49][50] Question: Updates on expedited review partners - Management confirmed more than 10 partners are in expedited review pathways, with significant indications including Parkinson's disease and drug-resistant epilepsy [60] Question: Timeline for expansion into neuro-oncology - Management emphasized the strength of their commercial team and the importance of upcoming clinical data to support expansion into neuro-oncology [62]

Lululemon Athletica (NasdaqGS:LULU) Q4 2026 Earnings call March 17, 2026 04:30 PM ET Company ParticipantsAndré Maestrini - Interim Co-CEO, President, and Chief Commercial OfficerBrooke Roach - Managing Director of Equity ResearchDana Telsey - CEO and Chief Research OfficerHoward Tubin - VP of Investor RelationsLorraine Hutchinson - Managing DirectorMeghan Frank - Interim Co-CEO and CFOMichael Binetti - Senior Managing DirectorPaul Lejuez - Managing DirectorConference Call ParticipantsAdrienne Yih - Managing ...

Financial Data and Key Metrics Changes - As of December 31, 2025, the company's cash and cash equivalents were $9.9 million, and in January 2026, it raised $22.3 million in gross proceeds from a public offering, extending its runway for operations [24][25] - The net loss for the fourth quarter of 2025 was $31.9 million, compared to $25.8 million in the same period the previous year [27] - Research and development expenses decreased to $9.4 million from $12.4 million year-over-year, while selling, general, and administrative expenses fell to $5.1 million from $6.8 million [25][26] Business Line Data and Key Metrics Changes - The rice program remains a core revenue generator, with seven rice customers representing a potential annual royalty opportunity of over $200 million [9][48] - The sustainable ingredients program has completed pre-commercial pilot runs for two biofragrance products, leading to the first customer payment in Q4 2025, with potential annual royalties estimated between $20 million and $40 million [15][16] Market Data and Key Metrics Changes - The company is targeting 5-7 million acres in the Americas for its rice traits, with potential expansion into India, which has approximately 120 million acres of rice cultivation [46][48] - The EU's recent political agreement on New Genomic Techniques legislation opens up approximately 100 million acres of greenfield opportunity in Europe, which has historically restricted GMO technologies [17][35] Company Strategy and Development Direction - The company is transitioning to a commercially driven model, focusing on gene editing as a core technology for agricultural innovation [4][5] - Cibus aims to build long-term shareholder value through a licensing and royalty framework tied to its gene editing capabilities, emphasizing ongoing relationships with seed companies [8][9] - The company is expanding its partnerships in Latin America and India, with plans for commercial launches in 2027 and 2030, respectively [10][12] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a pivotal year focused on execution and momentum, with expectations for significant advancements in rice commercialization and sustainable ingredients [29][30] - The regulatory landscape is evolving positively, with the EU's new legislation expected to catalyze commercial opportunities and partnerships [17][30] Other Important Information - The company has streamlined operations, reducing annual net cash usage to approximately $30 million or less in 2026, which supports its focus on near-term revenue [27][66] - The company has consolidated operations from its Oberlin facility into its San Diego headquarters, which is part of its cost-saving initiatives [27] Q&A Session Summary Question: Impact of EU NGT framework on CapEx for canola WOSR program - Management highlighted that the EU regulatory progress opens up significant opportunities for gene editing in Europe, particularly for winter oilseed rape, which is a major crop [34][35] Question: Next steps for rice commercialization in Latin America - Management outlined the process of editing elite genetics and the partnership with Interoc for commercialization in Ecuador and Colombia, with a focus on chemical registration and trait work [38][40] Question: Trend line for acres touched by technology - Management indicated a target of 5-7 million acres in the Americas, with potential for an additional 200 million acres in India by the end of the decade [46][48] Question: Maximum throughput for gene edits as a service - Management discussed the scalability of their gene editing platform, emphasizing the efficiency gained through automation and AI, which allows for managing multiple crops and lines [50][53] Question: Royalty rates for gene edits as a service - Management noted that the speed and scalability of their gene editing process allow for favorable negotiations on trait royalties, as customers can see value added quickly [56] Question: Scale of fragrance projects - Management mentioned the potential to work on approximately 17 fragrances, with plans to accelerate the process once the initial products are commercialized [57]